142 related articles for article (PubMed ID: 27443691)
1. A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
Puglisi F; Bisagni G; Ciccarese M; Fontanella C; Gamucci T; Leo L; Molino A; Silva RR; Marchetti P
Future Oncol; 2016 Nov; 12(22):2589-2602. PubMed ID: 27443691
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
Petitjean A; Smith-Palmer J; Valentine W; Tehard B; Roze S
BMC Cancer; 2019 Feb; 19(1):140. PubMed ID: 30744578
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
[TBL] [Abstract][Full Text] [Related]
7. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Yamamoto Y; Yamashiro H; Toh U; Kondo N; Nakamura R; Kashiwaba M; Takahashi M; Tsugawa K; Ishikawa T; Nakayama T; Ohtani S; Takano T; Fujisawa T; Toyama T; Kawaguchi H; Mashino K; Tanino Y; Morita S; Toi M; Ohno S
Breast Cancer; 2021 Jan; 28(1):145-160. PubMed ID: 32715420
[TBL] [Abstract][Full Text] [Related]
8. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
[TBL] [Abstract][Full Text] [Related]
9. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
[TBL] [Abstract][Full Text] [Related]
11. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Diéras V; Wildiers H; Jassem J; Dirix LY; Guastalla JP; Bono P; Hurvitz SA; Gonçalves A; Romieu G; Limentani SA; Jerusalem G; Lakshmaiah KC; Roché H; Sánchez-Rovira P; Pienkowski T; Seguí Palmer MÁ; Li A; Sun YN; Pickett CA; Slamon DJ
Breast; 2015 Jun; 24(3):182-90. PubMed ID: 25747197
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Manso L; Palomo AG; Pérez Carrión R; Cassinello J; Gallegos Sancho I; Chacón López-Muñiz I; Olier C; Fernández-Aramburo A; Llorca C; González X; Llorente R; Torregrosa D; Álvarez I; Gálve E; Bueno C; Garau I; García MJ; González-Santiago S; Ballesteros AI; Blanco E; Galán A; González S; Perelló A; Cortés-Funes H; Grávalos C
Anticancer Res; 2015 Dec; 35(12):6941-50. PubMed ID: 26637920
[TBL] [Abstract][Full Text] [Related]
13. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
Dieras V; Pop S; Berger F; Dujaric ME; Beuzeboc P; Escalup L; Bidard FC; Cottu PH; LE Tourneau C; Piperno-Neumann S; Laurence V; Robain M; Asselain B; Pierga JY
Anticancer Res; 2017 Mar; 37(3):1403-1407. PubMed ID: 28314310
[TBL] [Abstract][Full Text] [Related]
14. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
15. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
16. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
Livi L; Bonomo P; Meattini I; Simontacchi G; Greto D; Desideri I; Meacci F; Scotti V; Cecchini S; Nori J; Sanchez LJ; Orzalesi L; Paiar F; Biti G
Med Oncol; 2013 Mar; 30(1):434. PubMed ID: 23283649
[TBL] [Abstract][Full Text] [Related]
18. First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
Schneeweiss A; Förster F; Tesch H; Aktas B; Gluz O; Geberth M; Hertz-Eichenrode MM; Schönegg W; Schumacher C; Kutscheidt A; Kiewitz C; Klawitter S; Schmidt M
Anticancer Res; 2016 Mar; 36(3):967-74. PubMed ID: 26976985
[TBL] [Abstract][Full Text] [Related]
19. Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
Mery B; Rowinski E; Vallard A; Jacquin JP; Simoens X; Magné N; Doucey P
Oncology; 2019; 97(1):1-6. PubMed ID: 30939479
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer.
Tiainen L; Tanner M; Lahdenperä O; Vihinen P; Jukkola A; Karihtala P; Paunu N; Huttunen T; Kellokumpu-Lehtinen PL
Anticancer Res; 2016 Dec; 36(12):6431-6438. PubMed ID: 27919965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
